ERAS compared with ACHV: revenue, margins and what each company keeps, and the suppliers and customers both name

ERASErasca, Inc.

Mkt capRevenueRevenue

ACHVAchieve Life Sciences, Inc.

Mkt capRevenueRevenue

Compare

ERASErasca, Inc.

ACHVAchieve Life Sciences, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ERAS 5

—Emerge Life Sciences, Pteunlistedsupplier

—Guangzhou Joyo Pharmatechunlistedsupplier

—Medshine Discoveryunlistedsupplier

—Novartis Pharmaunlistedsupplier

1 more · ERAS chain ›

Shared 0

No shared counterparties.

Only ACHV 4

—Sopharma, ADunlistedsupplier

—University of Bristolunlistedsupplier

—Adare Pharma Solutionsunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—

Kristen Slaoui

unlistedsupplier

ERASErasca, Inc.

14.96▲+6.47%

Mkt cap$4.9B

ACHVAchieve Life Sciences, Inc.

6.71▲+1.46%

Regular sessionNov 3 '26

Mkt cap$702.8M

Compare

Regular sessionNov 3 '26

ERASErasca, Inc.

ACHVAchieve Life Sciences, Inc.

14.96▲+6.47%

Price

6.71▲+1.46%

$4.9B

Mkt cap

$702.8M

ERAS14.96▲+6.47%vsACHV6.71▲+1.46%Regular sessionNov 3 '26